The case revolves around allegations that Novartis made an agreement in 2011 with Par Pharmaceutical, when Exforge (valsartan/amlodipine) was nearing the end of its patent life that was designed ...

It also covers generic medicines from Novartis' Sandoz unit that are used to treat heart failure and hypertension (amlodipine, bisoprolol, hydrochlorothiazide, furosemide and ramipril), high ...

TOKYO -- Swiss pharmaceutical company Novartis plans to start mass production of radiopharmaceuticals, a type of next-generation cancer treatment, in Japan in 2026, Nikkei has learned. The company ...